Data / Research funding / Hepatitis - B
Hepatitis - B: 229 NIH awards ($950.5M) to 114 organizations
229 NIH awards ($950.5M) in the NIH spending category Hepatitis - B, to 114 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
229 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Boston HIV CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,445,869 | January 15, 2007 | November 30, 2027 | KURITZKES, DANIEL R. | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| CURE CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,461,433 | January 1, 2007 | November 30, 2027 | SPECTOR, STEPHEN A | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Improvements to the Regional Biocontainment Research Facilities at the University of Missouri | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,667,997 | September 23, 2021 | February 28, 2025 | LORSON, CHRISTIAN L. | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| High-throughput proteomics using submicroliter amounts of plasma for comprehensive assessment of the immune status | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,147,391 | April 9, 2020 | March 31, 2026 | STEEN, HANNO | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| RADx Innovation Funnel for Hepatitis B Diagnostics - Coordination Center | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,074,004 | September 30, 2024 | September 29, 2026 | SCHACHTER, STEVEN C. | reporter.nih.gov |
| A novel diagnostic Kit for Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $3,993,675 | September 1, 2012 | August 31, 2025 | LU, XUANYONG | reporter.nih.gov |
| A systems immunology approach for predicting poor responses to Hepatitis B vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,255 | September 17, 2021 | August 31, 2026 | HERATI, RAMIN | reporter.nih.gov |
| A Rhesus Macaque Model of HIV and HBV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,842,980 | March 20, 2021 | February 28, 2026 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,618,437 | September 1, 2016 | June 30, 2026 | COOPER, STEWART | reporter.nih.gov |
| NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,593,236 | February 7, 2022 | January 31, 2027 | RIBEIRO, RUY M | reporter.nih.gov |
| Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,554,273 | September 12, 2025 | August 31, 2029 | HUANG, YUNDA | reporter.nih.gov |
| Human Genetic determinants of HBV recovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,412,348 | September 30, 1999 | December 31, 2026 | THOMAS, DAVID L | reporter.nih.gov |
| Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,411,692 | September 24, 2025 | August 31, 2030 | NAGGIE, SUSANNA | reporter.nih.gov |
| Immunologic correlates of functional cure of HBV with immune checkpoint blockade | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,338,136 | May 22, 2020 | April 30, 2026 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Lead optimization of Hepatitis B Virus ribonuclease H inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,253,243 | December 1, 2020 | November 30, 2026 | TAVIS, JOHN E | reporter.nih.gov |
| Examine Individual and Clinical Factors Affecting Liver Disease Management | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,219,854 | September 15, 2022 | May 31, 2027 | MA, GRACE X. | reporter.nih.gov |
| Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,186,484 | August 1, 2022 | July 31, 2027 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Novel macrophage mediated signals regulate the immunoregulatory environment of the neonatal liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,176,680 | September 15, 2025 | September 14, 2029 | NIJAGAL, AMAR | reporter.nih.gov |
| Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,156,556 | February 10, 2020 | April 30, 2030 | RICE, CHARLES M | reporter.nih.gov |
| GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,034,670 | June 5, 2018 | March 31, 2025 | NAKAAR, VALERIAN | reporter.nih.gov |
| Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,016,918 | September 30, 2024 | September 29, 2025 | SUMNER, LOUISE | reporter.nih.gov |
| Mechanisms of T Cell Quiescence and Exhaustion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,001,713 | March 1, 2019 | February 28, 2029 | SARKAR, SUROJIT | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Targeting hepatitis B virus cccDNA during HBV/HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,993,820 | August 20, 2024 | July 31, 2029 | PLOSS, ALEXANDER | reporter.nih.gov |
| Non-invasive etiology-adjusted precision liver cancer risk prediction | NIH | National Cancer Institute | 2025 | $2,876,456 | August 5, 2025 | July 31, 2029 | HOSHIDA, YUJIN | reporter.nih.gov |
| Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,836,440 | July 15, 2020 | June 30, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,802,377 | February 15, 2020 | January 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,557,384 | April 12, 2021 | March 31, 2026 | JUON, HEE-SOON | reporter.nih.gov |
| First-in-human study of a potent anti-HBsAg neutralizing antibody | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,534,231 | March 20, 2023 | February 28, 2027 | CASKEY, MARINA | reporter.nih.gov |
| HBV Capsid Effectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,475,992 | June 1, 2017 | February 28, 2027 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Molecular Magnetic Resonance Imaging of Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,451,935 | August 1, 2019 | November 30, 2029 | GALE, ERIC MICHAEL | reporter.nih.gov |
| New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,444,033 | March 10, 2022 | February 28, 2027 | OSNA, NATALIA ALEKSANDR | reporter.nih.gov |
| The role of IL-17 signaling in alcohol-induced HCC | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,322,600 | August 6, 2021 | May 31, 2027 | KISSELEVA, TATIANA | reporter.nih.gov |
| Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,286,418 | July 1, 2024 | May 31, 2029 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Mechanisms of hepatitis B virus cccDNA formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,246,607 | May 15, 2020 | April 30, 2025 | PLOSS, ALEXANDER | reporter.nih.gov |
| Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,594 | August 20, 2021 | June 30, 2027 | REMISZEWSKI, STACY | reporter.nih.gov |
| Mechanisms of Hepadnavirus Assembly and Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,212,330 | February 15, 1999 | August 31, 2028 | HU, JIANMING | reporter.nih.gov |
| HBV-specific T cell immunity in HBV/HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,189,677 | August 1, 2025 | July 31, 2028 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| Understanding the Multilevel Drivers of Liver Cancer Disparities | NIH | National Cancer Institute | 2021 to 2023 | $2,174,412 | August 16, 2019 | July 31, 2025 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Structural characterization of native HBV capsids and virions from human cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,112,197 | June 14, 2023 | May 31, 2028 | WANG, JOSEPH CHE-YEN | reporter.nih.gov |
| Microchip for HBV testing using HIV-infected blood samples | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,012,162 | February 6, 2023 | November 30, 2024 | SHAFIEE, HADI | reporter.nih.gov |
| Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,982,398 | June 1, 2019 | May 31, 2024 | BURWITZ, BENJAMIN J | reporter.nih.gov |
| Human mechanisms of virus persistence in an AAV-based mouse model of chronic HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,966,264 | May 6, 2020 | April 30, 2026 | ROBEK, MICHAEL | reporter.nih.gov |
| Molecular Mechanisms of HBV cccDNA Formation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,933,309 | March 11, 2016 | June 30, 2027 | GUO, HAITAO | reporter.nih.gov |
| Developing a renewable and dissectible human liver for the study of HBV/HCV infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,000 | August 18, 2022 | July 31, 2027 | WU, XIANFANG | reporter.nih.gov |
| Maternal effect on offspring immunity against hepatitis B virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,925,049 | July 3, 2019 | June 30, 2025 | OU, J.-H. JAMES | reporter.nih.gov |
| Modeling Viral and T Lymphocyte Dynamics | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,866,528 | December 23, 2019 | November 30, 2025 | PERELSON, ALAN S | reporter.nih.gov |
| Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,857,031 | September 1, 2019 | August 31, 2025 | VINIKOOR, MICHAEL JEFFREY | reporter.nih.gov |
| Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,831,148 | September 1, 2022 | November 30, 2025 | SLAYDEN, RICHARD | reporter.nih.gov |
| Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,783,750 | April 1, 2020 | March 31, 2026 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| In search of an HBV cure: novel model systems and targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,782,852 | June 10, 2019 | May 31, 2024 | RICE, CHARLES M | reporter.nih.gov |
| A new humanized mouse model to study HBV gene editing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,705,880 | August 1, 2024 | July 31, 2029 | JEROME, KEITH R | reporter.nih.gov |
| Role of Base Excision Repair in Limiting Hepatocellular Carcinomas | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $1,650,684 | January 1, 2020 | October 31, 2024 | LLOYD, R. STEPHEN | reporter.nih.gov |
| Autophagy and the Replication of Hepatitis B Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,650,000 | February 3, 2020 | January 31, 2026 | OU, J.-H. JAMES | reporter.nih.gov |
| Developing Woodchucks Susceptible to Hepatitis B Virus Infection by Modifying the Virus or Host | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,621,356 | July 17, 2024 | June 30, 2029 | MENNE, STEPHAN | reporter.nih.gov |
| Altering Hepatitis B Virus assembly through pharmacological intervention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,572,240 | May 6, 2020 | April 30, 2026 | GUMBART, JAMES C. | reporter.nih.gov |
| Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,568,998 | June 12, 2024 | May 31, 2029 | RICE, CHARLES M | reporter.nih.gov |
| Dissecting Hepatitis B Vaccine Adjuvant Effects on Immune Responses and the HIV Reservoir in PLWH | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,567,217 | July 25, 2024 | May 31, 2029 | COX, ANDREA L | reporter.nih.gov |
| Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,566,354 | September 24, 2018 | August 31, 2024 | SU, LISHAN | reporter.nih.gov |
| Long-acting Antiviral Treatment for HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,562,010 | July 10, 2024 | June 30, 2029 | HO, RODNEY J.Y. | reporter.nih.gov |
| Epigenetic Regulation of HBV cccDNA Transcription | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,551,736 | June 16, 2020 | May 31, 2026 | GUO, HAITAO | reporter.nih.gov |
| ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,549,999 | April 3, 2023 | August 25, 2025 | ZHANG, YANG-YUAN | reporter.nih.gov |
| HBV cccDNA transcriptional silencing with and without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,548,735 | July 22, 2024 | May 31, 2029 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Influence of integrant-derived HBV RNAs encoding the envelope proteins on HBV life cycle | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,537,333 | February 4, 2022 | January 31, 2027 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B Trial) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,534,174 | May 18, 2020 | March 31, 2026 | DIONNE, JODIE ANN | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2022 to 2023 | $1,519,485 | July 1, 2022 | February 29, 2024 | ZHANG, XUEHONG | reporter.nih.gov |
| HBV RNaseH inhibitors: Effects on HBV biology and resistance development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,515,000 | December 2, 2019 | November 30, 2025 | TAVIS, JOHN E | reporter.nih.gov |
| Development of a hamster model for hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,485,242 | August 9, 2024 | July 31, 2029 | WANG, ZHONGDE | reporter.nih.gov |
| Hepatitis B virus e antigen in viral persistence | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,485,000 | February 20, 2017 | January 31, 2028 | OU, J.-H. JAMES | reporter.nih.gov |
| Multimode Observation of Virus Capsid Assembly | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,480,293 | March 14, 2016 | July 31, 2027 | ZLOTNICK, ADAM | reporter.nih.gov |
| Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,455,547 | July 9, 2020 | June 30, 2026 | PEPPA, DIMITRA | reporter.nih.gov |
| Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis | NIH | National Cancer Institute | 2021 to 2024 | $1,430,166 | December 1, 2019 | November 30, 2025 | MCLACHLAN, ALAN | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2024 to 2025 | $1,426,107 | July 1, 2022 | June 30, 2027 | ZHANG, XUEHONG | reporter.nih.gov |
| Cell surface receptors promoting hepatitis B virus infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,406,502 | July 15, 2020 | April 30, 2024 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| A proteomics atlas of HIV/HBV infections for curing HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,381,244 | August 1, 2024 | June 30, 2029 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| Novel mouse models of hepatitis B virus infection and replication | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,373,666 | June 21, 2024 | April 30, 2029 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| Hepatitis B virus integrations in KMT2B drive hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,297,237 | July 15, 2022 | June 30, 2027 | CAO, JIAN | reporter.nih.gov |
| Role of Human Apolipoprotein E in Hepatitis B Virus Infection and Morphogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,261,056 | September 22, 2020 | August 31, 2024 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| Collaborative Integration of Hepatitis B Molecular Virology and Mathematical/Computational Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,242,317 | January 15, 2019 | June 30, 2025 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| Mechanisms of Early-life Immunity Associated with HIV-1 Vaccine-induced Neutralizing Antibody Responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,239,565 | August 20, 2025 | June 30, 2030 | WILLIAMS, WILTON B | reporter.nih.gov |
| Leveraging HIV care infrastructure for implementation of context-adapted liver cancer comprehensive control strategies in Uganda: The LC3 Study | NIH | National Cancer Institute | 2024 to 2025 | $1,232,605 | September 3, 2024 | August 31, 2029 | KIRK, GREGORY D | reporter.nih.gov |
| Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation | NIH | National Cancer Institute | 2024 to 2025 | $1,208,126 | April 1, 2024 | March 31, 2029 | DEMEHRI, SHADMEHR | reporter.nih.gov |
| Epitranscriptomic regulation of HBV gene expression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,184,583 | March 1, 2019 | February 29, 2024 | SIDDIQUI, ALEEM | reporter.nih.gov |
| Developmental regulation of HBV biosynthesis by Ten-eleven translocation (Tet) methylcytosine dioxygenases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,173,588 | June 9, 2023 | May 31, 2028 | MCLACHLAN, ALAN | reporter.nih.gov |
| Testing of a Novel Inhaled Clofazimine (CFZ) Dry Powder Formulation in a Mouse Model of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,164,080 | August 1, 2023 | June 30, 2025 | ENDSLEY, JANICE | reporter.nih.gov |
| Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,131,736 | August 15, 2017 | July 31, 2023 | FRIEDMANN, PETER D | reporter.nih.gov |
| Impact of HIV co-infections and comorbidities on circadian rhythm in the liver | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,120,539 | August 15, 2024 | May 31, 2029 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| How does a metallofactor in Hepatitis B viral protein X orchestrate pathogenesis and liver cancer | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,115,277 | July 5, 2019 | June 30, 2024 | PANDELIA, MARIA-EIRINI | reporter.nih.gov |
| Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine | NIH | National Cancer Institute | 2023 to 2025 | $1,112,955 | February 1, 2023 | January 31, 2028 | SU, YING-HSIU | reporter.nih.gov |
| The role of neutralizing antibodies in natural and treatment-induced control of hepatitis B with and without HIV-1 co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,101,905 | January 24, 2023 | December 31, 2027 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| The Role of p53-R249S’s GOF in HCC development | NIH | National Cancer Institute | 2021 to 2023 | $1,072,557 | January 1, 2019 | December 31, 2024 | LU, HUA | reporter.nih.gov |
| qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents | NIH | National Cancer Institute | 2021 to 2022 | $964,654 | March 1, 2019 | August 31, 2023 | JOHNSTON, PAUL A. | reporter.nih.gov |
| The Role of HBeAg in HBV Persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $907,565 | August 10, 2018 | June 30, 2030 | GUO, HAITAO | reporter.nih.gov |
| Novel Hepatitis B Vaccine and Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $883,119 | August 21, 2024 | July 31, 2025 | LAW, MANSUN | reporter.nih.gov |
| HBV cccDNA and integrated DNA in HIV coinfection and HBV monoinfection | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $847,428 | August 3, 2023 | July 31, 2025 | LAU, DARYL T | reporter.nih.gov |
| Antiviral prophylaxis and infant vaccination to prevent perinatal hepatitis B infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $842,795 | February 15, 2018 | January 31, 2025 | JOURDAIN, GONZAGUE JOSEPH | reporter.nih.gov |
| Immune analysis of the HBsAg seroclearance response terminating chronic HBV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $814,790 | November 20, 2024 | October 31, 2029 | BARON, JODY L | reporter.nih.gov |
| Mechanisms of HBV cccDNA transcriptional regulation in persons with and without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $810,981 | August 14, 2018 | July 31, 2025 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Spatial omics to understanding HBV control in people with HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $806,208 | September 4, 2025 | August 31, 2030 | SCHWARTZ, ROBERT E | reporter.nih.gov |
| Characterizing Hepatitis B Transmission in Congolese Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $803,494 | June 23, 2020 | May 31, 2026 | THOMPSON, PEYTON J | reporter.nih.gov |
| Proteogenomics-driven therapeutic discovery in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2024 | $797,641 | April 1, 2020 | March 31, 2026 | ZHANG, BING | reporter.nih.gov |
| Helicobacter Infection and Liver Cancer Risk among African Americans and Whites in the United States | NIH | National Cancer Institute | 2024 to 2025 | $793,720 | July 16, 2021 | August 31, 2026 | ZHANG, XUEHONG | reporter.nih.gov |
| Characterization of silently HBV-infected hepatocytes in HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $779,416 | August 14, 2018 | July 31, 2023 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Adaptive Liver Tolerance via LSECs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $777,500 | September 19, 2018 | August 31, 2023 | CRISPE, IAN NICHOLAS | reporter.nih.gov |
| Human factors-designed triple test for HIV, HBV, and HCV infection in whole blood using target amplification, signal amplification, and crumpled graphene biosensor readout | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $776,341 | September 16, 2025 | August 31, 2030 | CUNNINGHAM, BRIAN T. | reporter.nih.gov |
| The Structural Biology of HBV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $757,618 | April 1, 2019 | November 30, 2024 | ZLOTNICK, ADAM | reporter.nih.gov |
| A novel CRISPR/Cas12 system targeting HBV DNA for gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $725,466 | November 1, 2024 | February 28, 2025 | YAO, ZHI Q. | reporter.nih.gov |
| Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors | NIH | National Cancer Institute | 2024 to 2025 | $657,145 | May 14, 2024 | April 30, 2027 | CAO, SHUGENG | reporter.nih.gov |
| Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 | $652,359 | September 14, 2018 | August 31, 2023 | MISHRA, LOPA | reporter.nih.gov |
| HBV Capsid Effectors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $635,652 | June 1, 2017 | March 15, 2022 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Molecular analysis of mother-to-child transmission of hepatitis B virus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $621,698 | April 1, 2025 | March 31, 2030 | OU, J.-H. JAMES | reporter.nih.gov |
| Evaluating HBVZ10-Based Therapies for cccDNA Clearance: Virological Foundation and Synergistic Combinations | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $606,178 | August 1, 2025 | July 31, 2027 | ZHANG, YONG-YUAN | reporter.nih.gov |
| Novel assay to detect integrated HBV DNA in urine of chronic hepatitis B patients | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $604,165 | December 11, 2021 | November 30, 2024 | LIN, SELENA | reporter.nih.gov |
| B-SMART - Broadly neutralizing antibodies for SaRNA Mediated Antiviral Response Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $599,989 | August 1, 2025 | July 31, 2027 | HARLOW, MARK LEE | reporter.nih.gov |
| Therapeutic vaccine platform to boost immune responses in Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $599,471 | August 1, 2025 | July 31, 2027 | ANTHONY, KAREN G. | reporter.nih.gov |
| Development of a PCR assay for quantitative detection of HBV cccDNA | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $595,802 | March 7, 2023 | February 28, 2025 | LIN, SELENA | reporter.nih.gov |
| Biomarkers for Early Detection of Hepatitis B-Related Hepatocellular Carcinoma in Hispanics | NIH | National Cancer Institute | 2025 | $580,238 | January 10, 2025 | December 31, 2029 | DEBES, JOSE DANIEL | reporter.nih.gov |
| Identifying and modulating therapeutic targets in a model of hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $548,297 | August 16, 2018 | July 31, 2023 | BARON, JODY L | reporter.nih.gov |
| Simulation Modeling of Hepatitis B Virus Elimination Strategies in Cote d'Ivoire | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $543,089 | August 1, 2022 | July 31, 2027 | MOHAREB, AMIR | reporter.nih.gov |
| A single biosensors for the simultaneous molecular detection of HIV and Hepatitis B and C viruses at resource-limited settings | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $537,619 | March 1, 2025 | February 29, 2028 | CHUMBIMUNI-TORRES, KARIN | reporter.nih.gov |
| Advancing High-Resolution Charge Detection-Mass Spectrometry | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $536,228 | September 24, 2024 | August 31, 2027 | JARROLD, MARTIN F | reporter.nih.gov |
| Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $529,157 | May 8, 2020 | April 30, 2025 | OCAMA, PONSIANO | reporter.nih.gov |
| Primary cell culture models of HIV/HBV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $526,396 | July 14, 2023 | June 30, 2025 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| Virus-host interactions for a cure against HBV | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $510,306 | August 15, 2024 | July 31, 2025 | MICHAILIDIS, ELEFTHERIOS | reporter.nih.gov |
| Discovery of inhibitors that target HBx for the treatment of chronic HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $506,623 | December 15, 2020 | November 30, 2023 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Clinical Decision Support to Promote Immigrant Child Health Screening | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $505,937 | February 4, 2022 | January 31, 2025 | YUN, KATHERINE M | reporter.nih.gov |
| Impact of Hepatitis C and HIV coinfection on biological aging and hepatocellular carcinoma risk | NIH | Fogarty International Center | 2022 to 2023 | $500,450 | July 1, 2022 | June 30, 2025 | DEBES, JOSE DANIEL | reporter.nih.gov |
| Development of a Multiplex Quantitative PCR Assay for HIV and Hepatitis B Virus, for Low- and middle Income Countries | NIH | Fogarty International Center | 2021 to 2025 | $499,480 | August 23, 2021 | May 31, 2026 | FOFANA, DJENEBA BOCAR | reporter.nih.gov |
| A splicing-generated protein of hepatitis B virus in chronic viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $492,000 | July 1, 2024 | December 31, 2025 | TONG, SHUPING | reporter.nih.gov |
| Cell surface receptors promoting hepatitis B virus infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $469,782 | July 15, 2020 | April 30, 2026 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| Minimally-instrumented home HIV detection and care linkage system | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $461,436 | September 12, 2019 | August 31, 2023 | BAU, HAIM H | reporter.nih.gov |
| Hepatitis B virus cccDNA | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $457,500 | August 15, 2018 | July 31, 2023 | SEEGER, CHRISTOPH | reporter.nih.gov |
| Hepatitis B virus integrations in KMT2B drive hepatocellular carcinoma | NIH | National Cancer Institute | 2022 | $453,403 | July 15, 2022 | June 30, 2023 | CAO, JIAN | reporter.nih.gov |
| Explore hepatitis B virus preS2 mutants as immune escape mutants | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $451,000 | November 10, 2022 | October 31, 2025 | LI, JISU | reporter.nih.gov |
| Explore furin as an antiviral target to block hepatitis B virus e antigen production | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $450,875 | September 24, 2021 | February 29, 2024 | TONG, SHUPING | reporter.nih.gov |
| Exploring Hepatitis B Virus PreCore Gene Functions in Woodchucks | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $450,675 | December 14, 2023 | October 31, 2026 | MENNE, STEPHAN | reporter.nih.gov |
| Post-translational regulation of hepatitis B virus large envelope protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $450,500 | June 1, 2021 | May 31, 2024 | LI, JISU | reporter.nih.gov |
| Unraveling sources of hepatitis B surface antigen before and after nucleos(t)ide analogue treatment in People with HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $450,313 | March 25, 2021 | March 1, 2025 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Identifying the source of hepatitis B surface antigen in people with hepatitis B-HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $450,313 | July 12, 2021 | June 30, 2024 | BALAGOPAL, ASHWIN | reporter.nih.gov |
| Dissecting Structural Details of Hepadnavirus Subviral Particles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $445,995 | May 19, 2021 | April 30, 2024 | WANG, CHE-YEN | reporter.nih.gov |
| IL-1β as a novel therapeutic agent against hepatitis B virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $445,372 | January 1, 2024 | November 30, 2026 | OU, J.-H. JAMES | reporter.nih.gov |
| Biomarkers of Replication and Injury in HBV/HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $443,976 | July 12, 2021 | June 30, 2024 | SHERMAN, KENNETH E | reporter.nih.gov |
| Small molecule inhibitors of HBx that decrease hepatitis B virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $440,000 | July 15, 2021 | June 30, 2024 | CRAWFORD, SUE ELLEN | reporter.nih.gov |
| Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $440,000 | September 22, 2023 | August 31, 2026 | DU, YANMING | reporter.nih.gov |
| Creation of a transgenic pig model permissive to HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $440,000 | August 6, 2025 | July 31, 2027 | KRUSE, ROBERT LAYNE | reporter.nih.gov |
| Role of Human Apolipoprotein E in Hepatitis B Virus Infection andMorphogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $438,751 | September 22, 2020 | August 31, 2025 | LUO, GUANGXIANG GEORGE | reporter.nih.gov |
| High-density flagellin-displayed virus-like particle for universal influenza vaccine development' | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $433,125 | June 11, 2021 | May 31, 2024 | CHEN, XINYUAN | reporter.nih.gov |
| Pathogenesis of HIV and HBV Co-Infection in a Humanized Mouse Model | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $431,938 | February 15, 2021 | January 31, 2023 | AMBROSE, ZANDREA | reporter.nih.gov |
| High throughput screening and preclinical development of HBV cccDNA inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $426,392 | January 1, 2024 | December 31, 2026 | GUO, HAITAO | reporter.nih.gov |
| Regulation of HDV life cycle by the immune response to HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | June 16, 2021 | May 31, 2024 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Role of DDX5 in Hepatitis B virus transcription and hepatocarcinogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,559 | February 16, 2023 | June 30, 2025 | KAZEMIAN, MAJID | reporter.nih.gov |
| Enhancement of Human Immune System Development in Mouse Models | NIH | Office of the Director, National Institutes of Health | 2022 to 2023 | $422,125 | July 1, 2022 | June 30, 2024 | POLUEKTOVA, LARISA Y | reporter.nih.gov |
| Chemically ligated-guide RNA (lgRNA)-based CRISPR/Cas9 gene editing for elimination of hepatitis B virus cccDNA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $421,875 | January 1, 2024 | December 31, 2026 | GUO, JU-TAO | reporter.nih.gov |
| Dual specific gene editing drugs delivered by nanoparticles targeting HBV/HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $419,845 | May 10, 2021 | April 30, 2024 | YAO, ZHI Q. | reporter.nih.gov |
| Regulation of the life cycle of HDV by the drug resistance mutations of HBV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $419,500 | July 23, 2021 | June 30, 2024 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Characterization of 5'-human-HBV-3' RNA species transcribed from integrated HBV DNA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $419,275 | February 1, 2024 | December 31, 2026 | GUDIMA, SEVERIN O | reporter.nih.gov |
| Hepatitis B virus e antigen in viral persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $412,500 | June 20, 2017 | January 31, 2023 | OU, J.-H. JAMES | reporter.nih.gov |
| The Role of RNA Structure in the Hepatitis B Virus Lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $407,024 | March 11, 2021 | February 29, 2024 | BOUCHARD, MICHAEL J. | reporter.nih.gov |
| HIV Tat and HBV HBx in HIV/HBV Coinfection-associated Liver Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $407,024 | March 19, 2021 | February 29, 2024 | BOUCHARD, MICHAEL J. | reporter.nih.gov |
| Engineering exosomes for new gRNA/Cas therapeutics to eliminate HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $398,829 | January 1, 2024 | June 7, 2026 | YAO, ZHI Q. | reporter.nih.gov |
| Toward a Curative Treatment for HBV with cccDNA-Targeting Peptide Nucleic Acids | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $391,955 | February 15, 2024 | December 31, 2026 | GAGNON, KEITH THOMAS | reporter.nih.gov |
| Mechanisms of HBV-Induced Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $387,500 | June 23, 2017 | May 31, 2022 | SIDDIQUI, ALEEM | reporter.nih.gov |
| A novel multi-analyte algorithmic assay diagnostic for hepatocellular carcinoma (HCC). | NIH | National Cancer Institute | 2025 | $364,763 | June 20, 2025 | November 30, 2026 | BISWAL, BOBBY KUMAR | reporter.nih.gov |
| Use of Peripheral Blood Mononuclear Cells Mitochondrial DNA Content to Detect Hepatocellular Carcinoma in Hepatitis B Virus Infected Nigerians. | NIH | Fogarty International Center | 2023 to 2025 | $357,587 | July 27, 2023 | April 30, 2028 | ADISA, RAHMAT ADETUTU | reporter.nih.gov |
| Bioinspired Point of Care Testing for HIV/HBV Co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $354,570 | July 7, 2025 | June 30, 2030 | DRAZ, MOHAMED | reporter.nih.gov |
| Understanding the Determinants of Racial/Ethnic Disparities in Liver Cancer and Chronic Liver Disease in Understudied and High-Risk Populations | NIH | National Cancer Institute | 2021 | $350,258 | March 6, 2018 | August 31, 2023 | SETIAWAN, VERONICA WENDY | reporter.nih.gov |
| Mechanisms of Hepatocyte Transformation by the Hepatitis B Virus X Protein | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $344,520 | May 1, 1993 | February 28, 2023 | ANDRISANI, OURANIA M. | reporter.nih.gov |
| Translational Development of a Small Molecule for the Treatment of HBV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $320,863 | September 22, 2025 | August 31, 2027 | KAY, HEIDI A | reporter.nih.gov |
| Computational modeling of viral capsid and bacterial microcompartment assembly | NIH | National Institute of General Medical Sciences | 2021 | $309,999 | December 1, 2008 | May 31, 2023 | HAGAN, MICHAEL F | reporter.nih.gov |
| A new class of antiviral directed at HBV capsid protein | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $306,500 | January 1, 2024 | August 31, 2025 | NAIR, SMITA | reporter.nih.gov |
| NIAID Division of AIDS (DAIDS) Chemotherapeutic Agents Repository | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $304,084 | December 15, 2023 | December 14, 2025 | reporter.nih.gov | |
| A New HBV Drug For Establishing Durable Antiviral Efficacy of HBV Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | March 1, 2021 | February 28, 2023 | ZHANG, YONG-YUAN | reporter.nih.gov |
| Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | July 1, 2022 | June 30, 2024 | DU, YANMING | reporter.nih.gov |
| Development of STAR Editors (CRISPR-Cas9/lgRNA-ssDNA) for the cure of chronic hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | August 9, 2022 | July 31, 2024 | ZHONG, MINGHONG | reporter.nih.gov |
| Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $300,000 | September 11, 2025 | August 31, 2027 | FULLER, DEBORAH H. | reporter.nih.gov |
| A Simple Multiplexed Platform for Self-Administered HIV and Hepatitis B Testing | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,982 | August 1, 2024 | July 31, 2028 | NG, RAINER | reporter.nih.gov |
| Development of an Ultrasensitive, Rapid and Easy-to-Use At-Home Molecular Test for HCV, HBV AND HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,961 | August 1, 2024 | April 30, 2025 | JANGAM, SUJIT | reporter.nih.gov |
| An Easy-to-Use, Low-Cost Triplex RDT for the Simultaneous Diagnosis of HBV, HCV, AND HIV Infection, Compatible with Field Use in LMICS and At-Home Use in the US | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,659 | August 1, 2024 | July 31, 2025 | BIAMONTE, MARCO ANTONIO | reporter.nih.gov |
| Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $298,323 | July 21, 2020 | June 30, 2023 | ARON, ZACHARY DAVID | reporter.nih.gov |
| Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $275,211 | April 14, 2023 | September 30, 2024 | BERUBE, BRYAN | reporter.nih.gov |
| Ethanol suppresses HBV peptide-MHC Class I presentation on hepatocytes | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $273,420 | August 1, 2018 | October 20, 2023 | GANESAN, MURALI | reporter.nih.gov |
| A development strategy to obtain IND approval of HBVZ10, a new HBV cure therapy candidate | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $258,750 | September 1, 2025 | August 31, 2026 | ZHANG, YONG-YUAN | reporter.nih.gov |
| Detecting drug-resistant HBV and HCV variants using a DDS probe array | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $253,385 | February 2, 2021 | January 31, 2022 | SHAFER, DAVID A | reporter.nih.gov |
| Host Response to Hepatitis Delta Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $249,000 | April 1, 2025 | March 31, 2027 | SAITO, TAKESHI | reporter.nih.gov |
| Engineering viral nanoparticles for TLR agonist-based multi-functional cancer immunotherapies | NIH | National Cancer Institute | 2025 | $249,000 | May 1, 2024 | August 31, 2028 | ZHAO, ZHONGCHAO | reporter.nih.gov |
| Metabolic basis for lipid abnormality with anti-HIV tenofovir prodrugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $243,000 | September 4, 2020 | August 31, 2024 | YAN, BINGFANG | reporter.nih.gov |
| Regulation of Genome Stability and Structure by the Nucleosome Remodeler HELLS in Leukemia | NIH | National Cancer Institute | 2023 to 2024 | $213,638 | September 1, 2023 | May 30, 2025 | PRESCOTT, NICHOLAS | reporter.nih.gov |
| Aflatoxin exposure and hepatocellular carcinoma in Mexico | NIH | Fogarty International Center | 2021 to 2022 | $210,818 | August 1, 2020 | April 30, 2023 | LAJOUS, MARTIN | reporter.nih.gov |
| Development of a semi-quantitative ligation-based assay for Hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $206,250 | January 1, 2020 | December 31, 2022 | CABODI, MARIO | reporter.nih.gov |
| Adherence and Intracellular Pharmacology of Tenofovir and HBV Suppression in People with HBV/HIV Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $185,275 | April 1, 2020 | March 31, 2024 | KWARA, AWEWURA JACOB | reporter.nih.gov |
| Development of a Novel Inhibitor for Hepatitis B | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $179,933 | May 21, 2020 | April 30, 2023 | BELL, THOMAS W. | reporter.nih.gov |
| The impact of a Hepatitis B birth dose vaccine on HBV immunogenicity and incidence in children in the DRC | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $179,695 | August 1, 2021 | July 31, 2026 | TULENKO, SAMANTHA | reporter.nih.gov |
| Spatial and molecular epidemiology of hepatitis B transmission in the Democratic Republic of the Congo | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $172,320 | April 1, 2022 | November 30, 2026 | MORGAN, CAMILLE | reporter.nih.gov |
| Transcriptomic Quantitation of Hepatitis B Virus Surface Antigen from Integration | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $151,500 | May 11, 2023 | April 30, 2026 | FAN, XIAOFENG | reporter.nih.gov |
| Viral and Host Determinants of Endosomal Trafficking during HBV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $111,881 | August 1, 2022 | July 31, 2025 | MCGINLEY, MEGAN | reporter.nih.gov |
| CD8+ T CELL REPROGRAMMING TO BOOST ANTIVIRAL POTENTIAL AGAINST CHRONIC INFECTION | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $108,000 | August 12, 2024 | June 30, 2026 | PERDOMO, FEDERICO | reporter.nih.gov |
| Quantifying the frequency and diversity of spliced HBV mRNAs in HIV-HBV co-infection and their role in modulating viral transcription and host immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $96,668 | August 1, 2023 | July 31, 2025 | GRUDDA, TANNER | reporter.nih.gov |
| Air pollution and health disparities in liver disease and cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $95,025 | July 15, 2020 | March 31, 2022 | VOPHAM, TRANG | reporter.nih.gov |
| Hepatic Priming of CD4+ T cells Directs Effective Hepatitis B Virus Immunity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $94,970 | March 15, 2024 | March 14, 2027 | CAREY, NICHOLAS DANIEL | reporter.nih.gov |
| Biochemical studies of aberrant chromatin regulation in cancer | NIH | National Cancer Institute | 2021 to 2022 | $94,288 | September 1, 2021 | August 31, 2023 | PRESCOTT, NICHOLAS | reporter.nih.gov |
| Unveiling a Novel Mechanism of Oncovirus-Induced Carcinogenesis | NIH | National Cancer Institute | 2025 | $78,500 | December 1, 2024 | November 30, 2026 | CAO, JIAN | reporter.nih.gov |
| Health-Related Quality of Life Among Adolescents and Young Adults Living with Chronic Hepatitis B: An Exploration of Family Context and Stigma | NIH | National Institute of Nursing Research | 2025 | $52,538 | December 1, 2025 | June 30, 2028 | BLOCK, SUZANNE | reporter.nih.gov |
| Biocatalytic generation of bioactive biaryl natural products | NIH | National Center for Complementary & Integrative Health | 2021 to 2022 | $43,852 | June 1, 2020 | June 30, 2022 | ZETZSCHE, LARA EMILY | reporter.nih.gov |
| Delineating the impact of human karyopherins on hepatitis B virus species tropism | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $32,974 | May 1, 2024 | April 30, 2025 | IJOMA, JENNY NNEKA | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $20,635 | June 1, 2021 | September 30, 2021 | GARCIA-MARTINEZ, J. VICTOR | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $18,894 | April 15, 2021 | August 14, 2021 | MCDONALD, JACOB | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $17,195 | April 15, 2021 | August 14, 2021 | TALTON, JAMES | reporter.nih.gov |
| HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $12,000 | November 4, 2021 | October 31, 2022 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $10,582 | April 15, 2021 | August 14, 2021 | SUBBIAN, SELVAKUMAR | reporter.nih.gov |
| 2020 International Meeting on the Molecular Biology of Hepatitis B Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $9,000 | July 9, 2021 | June 30, 2022 | ANDRISANI, OURANIA M. | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $8,746 | April 15, 2021 | August 14, 2021 | RAJUR, RAJ | reporter.nih.gov |
| 2023 International HBV Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $7,000 | July 12, 2023 | June 30, 2024 | TAVIS, JOHN E | reporter.nih.gov |
| Development of a Novel HBV Drug | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $6,500 | August 19, 2020 | October 15, 2021 | ZHANG, YONG-YUAN | reporter.nih.gov |
| 2024 International Meeting on the Molecular Biology of Hepatitis B Viruses (International HBV Meeting) | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $5,000 | August 6, 2024 | July 31, 2025 | PLOSS, ALEXANDER | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $4,382 | April 15, 2021 | August 14, 2021 | ERB, DENNIS | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles, CA | 3 | $550.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 14 | $28.8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 8 | $28.5 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 5 | $25.7 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 3 | $25 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 7 | $19.3 million | 0 | $0 |
| Universitat Bern | Bern | 1 | $16.8 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 4 | $16.4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 1 | $12.7 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 1 | $10.7 million | 0 | $0 |
| Chiang Mai University | Chiang Mai | 1 | $10.1 million | 0 | $0 |
| Rockefeller University | New York, NY | 5 | $9.3 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 5 | $8.2 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 3 | $7.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 8 | $7.1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 5 | $6.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $6.7 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 1 | $5.7 million | 0 | $0 |
| Triad National Security, LLC | Los Alamos, NM | 2 | $5.5 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $5.3 million | 0 | $0 |
| Princeton University | Princeton, NJ | 3 | $5.3 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 2 | $5.3 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 1 | $5.1 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 3 | $4.9 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 4 | $4.9 million | 0 | $0 |
| Duke University | Durham, NC | 2 | $4.7 million | 0 | $0 |
| Imcare Biotech, Inc. | Doylestown, PA | 2 | $4.4 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 2 | $4 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 1 | $3.9 million | 0 | $0 |
| Starks Associates, Inc. | Buffalo, NY | 1 | $3.7 million | 0 | $0 |
| California Pacific Med CTR Res Institute | San Francisco, CA | 1 | $3.6 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 2 | $3.5 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 1 | $3.2 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 3 | $3.1 million | 0 | $0 |
| Carogen Corporation | Hamden, CT | 1 | $3 million | 0 | $0 |
| Gryphon Scientific, LLC | Takoma Park, MD | 1 | $3 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 1 | $3 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 1 | $2.9 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 4 | $2.8 million | 0 | $0 |
| Indiana University | Bloomington, IN | 3 | $2.8 million | 0 | $0 |
| Hbvtech | Germantown, MD | 5 | $2.7 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 4 | $2.7 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 2 | $2.7 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 2 | $2.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 1 | $2.6 million | 0 | $0 |
| University of Washington | Seattle, WA | 2 | $2.3 million | 0 | $0 |
| Evrys Bio, LLC | Doylestown, PA | 1 | $2.2 million | 0 | $0 |
| Yale University | New Haven, CT | 2 | $2.2 million | 0 | $0 |
| Georgetown University | Washington, DC | 2 | $2.1 million | 0 | $0 |
| Baruch S. Blumberg Institute | Doylestown, PA | 3 | $2 million | 0 | $0 |
| Albany Medical College | Albany, NY | 1 | $2 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 1 | $1.9 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 4 | $1.8 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 1 | $1.8 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 2 | $1.6 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 1 | $1.6 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 1 | $1.6 million | 0 | $0 |
| East Tennessee State University | Johnson City, TN | 3 | $1.5 million | 0 | $0 |
| Utah State University | Logan, UT | 1 | $1.5 million | 0 | $0 |
| University College London | London | 1 | $1.5 million | 0 | $0 |
| Brandeis University | Waltham, MA | 2 | $1.4 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 2 | $1.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $1.2 million | 0 | $0 |
| JBS Science, Inc. | Doylestown, PA | 2 | $1.2 million | 0 | $0 |
| Baystate Medical Center, Inc. | Springfield, MA | 1 | $1.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 2 | $1.1 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 1 | $1.1 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 2 | $900,496 | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 1 | $847,428 | 0 | $0 |
| Institute of Research and Development | Marseille | 1 | $842,795 | 0 | $0 |
| Drexel University | Philadelphia, PA | 2 | $814,048 | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 1 | $776,341 | 0 | $0 |
| Purdue University | West Lafayette, IN | 2 | $768,079 | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 2 | $686,976 | 0 | $0 |
| University of Hawaii at Hilo | Hilo, HI | 1 | $657,145 | 0 | $0 |
| George Washington University | Washington, DC | 1 | $652,359 | 0 | $0 |
| Lynntech, Inc. | College Station, TX | 1 | $599,989 | 0 | $0 |
| L2 Diagnostics, LLC | New Haven, CT | 1 | $599,471 | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 1 | $537,619 | 0 | $0 |
| Infectious Diseases Institute | Kampala | 1 | $529,157 | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 1 | $505,937 | 0 | $0 |
| Univ of Sciences, Tech & Tech of Bamako | Bamako | 1 | $499,480 | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 1 | $461,436 | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 1 | $457,500 | 0 | $0 |
| RBHS -Cancer Institute of New Jersey | New Brunswick, NJ | 1 | $453,403 | 0 | $0 |
| University of Rhode Island | Kingston, RI | 1 | $433,125 | 0 | $0 |
| College of Medicine, University of Lagos | Lagos | 1 | $357,587 | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 1 | $354,570 | 0 | $0 |
| Jericho Sciences, LLC | Springfield, VA | 1 | $320,863 | 0 | $0 |
| Door Pharmaceuticals, LLC | Bloomington, IN | 1 | $306,500 | 0 | $0 |
| Fisher Bioservices, Inc. | Rockville, MD | 1 | $304,084 | 0 | $0 |
| Harlingene Life Sciences LLC | Doylestown, PA | 1 | $300,000 | 0 | $0 |
| Genelancet Biosciences INC | Doylestown, PA | 1 | $300,000 | 0 | $0 |
| Orlance, Inc. | Seattle, WA | 1 | $300,000 | 0 | $0 |
| Baebies, Inc. | Durham, NC | 1 | $299,982 | 0 | $0 |
| Arete Biosciences | Chicago, IL | 1 | $299,961 | 0 | $0 |
| Big Eye Diagnostics, Inc. | San Diego, CA | 1 | $299,659 | 0 | $0 |
| Microbiotix, INC | Worcester, MA | 1 | $298,323 | 0 | $0 |
| HDT Bio Corporation | Seattle, WA | 1 | $275,211 | 0 | $0 |
| Genetag Technology, Inc. | Atlanta, GA | 1 | $253,385 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 103 | $153,352,966 | 0 | $0 |
| 2024 | 120 | $133,762,344 | 0 | $0 |
| 2023 | 102 | $202,751,960 | 0 | $0 |
| 2022 | 113 | $240,688,012 | 0 | $0 |
| 2021 | 123 | $219,988,130 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 153 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 153 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 153 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.